Takeda begins real-world MM study

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said began it enrolling multiple myeloma patients in its global observational INSIGHT-MM study, which aims to track patterns in disease presentation, patient characteristics, treatment and outcomes. The pharma plans to enroll 5,000 MM patients and to follow them for at least five years. ...